NCT01373216View on ClinicalTrials.gov

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

December 31, 2014

Conditions
Coronary Artery DiseaseDecreased Left Ventricular Function
Interventions
DRUG

Exenatide

Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours

Trial Locations (1)

128 08

General University Hospital, Prague

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Charles University, Czech Republic

OTHER

NCT01373216 - Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass | Biotech Hunter | Biotech Hunter